Compare Consolidated Edison, Inc. (ED) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Consolidated Edison, Inc. vs Sana Biotechnology Inc — how do they compare? Consolidated Edison, Inc. trades at $107.67 (market cap $39.76B), while Sana Biotechnology Inc trades at $3.75 (market cap $1.13B). The key difference: Consolidated Edison, Inc. is far larger — about 35.2× Sana Biotechnology Inc's market cap, and Consolidated Edison, Inc. pays a 3.27% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| ED | SANA | |
|---|---|---|
Market Cap | $39.76B | $1.13B |
Sector | Utilities | Health |
52-Week High | $115.46 | $5.92 |
52-Week Low | $95.37 | $2.68 |
Enterprise Value | $66.61B | $1.05B |
Dividend Yield | 3.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Consolidated Edison (ED) trades at $106.3, down 1.56% today, near the consensus price target of $103.25. Recent Q2 2026 earnings beat estimates with EPS of $0.83, though Q1 missed. The stock shows a bearish technical trend with support at $105 and resistance at $108. Fundamentals are stable with 2025 revenue of $16.92B and net income margin of 12.53%, supported by consistent dividend payments.
ED offers steady income with a 3.2% dividend yield and regulated utility stability, but faces headwinds from high debt levels and mixed analyst sentiment (62.96% hold rating). Key risks include interest rate sensitivity and capital expenditure demands for grid upgrades. The stock suits defensive investors seeking reliable dividends amid moderate growth expectations.
SANA Biotechnology trades at $3.775, up 4.57% with strong technical momentum as moving averages signal bullish sentiment. The company shows significant financial challenges with negative ROE (-152.87%) and net income (-$244.17M in 2025), though recent analyst upgrades and clinical developments in cell therapy research provide optimism. Cash flow remains negative but improved from -$55M to -$14M year-over-year, while the stock benefits from 82% buy ratings from analysts.
Investment outlook balances high-risk fundamentals against promising biotechnology breakthroughs. The primary opportunity lies in successful clinical trial outcomes and market adoption of engineered cell therapies, while risks include sustained cash burn, execution challenges, and competitive pressures in the genomics space. Wall Street's $9.50 price target suggests substantial upside potential if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
